BSX · News · 20261106N
Acquisition / Partnership / Divestiture
BOSTON SCIENTIFIC CORP · 2026-11-06 · Importance 44 · Surprise 42 · In source text
Boston Scientific and Blackstone Life Sciences entered a $455 million co-funding collaboration to develop the VITALYST Temporary Percutaneous Transvalvular Circulatory Support System. The miniature heart pump is intended to treat acute myocardial infarction cardiogenic shock by increasing cardiac output and improving blood flow to vital organs. The partners aim to improve the efficacy, safety, and ease of use of mechanical circulatory support technologies for critically ill patients.
Key facts
- Boston Scientific Corp. and Blackstone Life Sciences are co-funding development of the VITALYST Temporary Percutaneous Transvalvular Circulatory Support System through a $455 million collaboration. source
- The VITALYST miniature heart pump is designed to treat acute myocardial infarction cardiogenic shock by increasing cardiac output and improving blood flow to vital organs. source
- The Boston Scientific–Blackstone Life Sciences partnership aims to enhance the efficacy, safety, and ease of use of mechanical circulatory support technologies for critically ill patients. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | negative | committed | — | Boston Scientific Corp. and Blackstone Life Sciences are co-funding development of the VITALYST Temporary Percutaneous Transvalvular… |